Search for astaxanthin and blood pressure and you will find confident claims that it relaxes blood vessels and brings readings down. Those claims are not invented. They trace back to a real and fairly consistent body of animal work, most of it in spontaneously hypertensive rats.
The problem is what happened when the same question was asked in people. Two separate meta-analyses have now pooled the human randomized trials, and neither found a significant effect on systolic or diastolic pressure. This article walks through what was measured, what was found, and why the animal-to-human gap here is wider than the marketing suggests.
Key Takeaways
- A 2020 meta-analysis of 14 randomized controlled trials found astaxanthin was not associated with systolic or diastolic blood pressure, and also not with fasting blood sugar, HbA1c, total cholesterol, LDL-C, triglycerides, BMI or body weight [1].
- The single positive finding in that analysis was a small rise in HDL cholesterol (weighted mean difference 1.47 mg/dL, 95% CI 0.32 to 2.63, p = 0.012) [1].
- An earlier meta-analysis of 7 trials and 280 participants found no significant effect on HDL-C either (p = 0.199), so even that one result is not replicated across reviews [2].
- A 2023 triple-blind trial in women with PCOS measured blood pressure directly at baseline and 8 weeks. Blood pressure does not appear among the outcomes that changed significantly, while several metabolic markers did [3].
- A cardiovascular review of astaxanthin grades the evidence explicitly: strong in vitro, moderate in animals, weak in humans [4].
- C-reactive protein is the one inflammatory marker with a dose and duration signal, and that is a different endpoint from blood pressure.
Where the Blood Pressure Claim Comes From
The mechanistic story is plausible. Astaxanthin sits inside cell membranes, spanning the lipid bilayer, and reduces lipid peroxidation there. Oxidative stress in the vascular wall reduces nitric oxide availability, and less nitric oxide means less vasodilation. An antioxidant that works at the membrane could, in principle, restore some of that.
Animal work has broadly supported the idea. A 2017 review of astaxanthin in cardiovascular health catalogues antihypertensive activity alongside antioxidant, anti-inflammatory, antidiabetic, renoprotective, lipid-lowering and anti-atherosclerotic effects [4]. What that same review does, and what supplement marketing generally does not, is grade the evidence by where it came from. Its wording is direct: the biological activities are supported by strong evidence in vitro, moderate evidence in animals, and weak evidence in humans [4].
That gradient is the entire story of this topic.
The 2020 Meta-Analysis: The Clearest Answer We Have
The most useful single piece of evidence is a 2020 systematic review and meta-analysis that searched Scopus, Web of Science, PubMed/Medline, Embase and Google Scholar and pulled 14 eligible randomized controlled trials into a quantitative analysis [1].
Its findings on the endpoints people care about:
- Systolic blood pressure: no significant association.
- Diastolic blood pressure: no significant association.
- Fasting blood sugar, HbA1c: no significant association.
- Total cholesterol, LDL-C, triglycerides: no significant association.
- BMI and body weight: no significant association.
- HDL cholesterol: a significant increase, weighted mean difference 1.473 mg/dL (95% CI 0.319 to 2.627, p = 0.012).
That HDL number deserves a moment of honesty. A rise of roughly 1.5 mg/dL is real in the statistical sense and small in the clinical sense. It is the kind of change that shows up when you pool enough participants, not the kind that moves a treatment decision.
The C-Reactive Protein Exception
The same analysis did find something on inflammation, but only under conditions. Levels of C-reactive protein fell only when astaxanthin was given for a relatively long period, at least 12 weeks (weighted mean difference -0.528 mg/L, 95% CI -0.990 to -0.066), and only at a high dose above 12 mg per day (-0.389, 95% CI -0.596 to -0.183) [1].
This is worth separating clearly from blood pressure. Inflammation and blood pressure are related over the long run, but a CRP change at 12 weeks is not a blood pressure result, and it should not be presented as one. If you see a page citing the CRP finding under a heading about hypertension, that is a substitution.
An Earlier Meta-Analysis Disagreed On HDL Too
A 2015 meta-analysis looked specifically at lipids and glucose across 7 randomized controlled trials (10 treatment arms, 280 participants; 163 on astaxanthin, 117 control) [2]. It found no significant effect on total cholesterol, LDL-C, HDL-C, triglycerides or glucose. HDL-C specifically came out at a weighted mean difference of +1.75 mg/dL with a 95% confidence interval of -0.92 to +4.42 and p = 0.199 [2].
Notice how close that point estimate is to the 2020 figure. Same direction, similar magnitude, but the confidence interval crosses zero, so it is not significant. The authors also reported that the result was robust: dropping any single study did not meaningfully change the estimate [2].
Two reviews, overlapping trials, one calls HDL significant and one does not. That is what a genuinely marginal effect looks like from the outside.
The Trial That Measured Blood Pressure And Found Other Things
One trial is particularly instructive because it did not set out to study blood pressure alone. A 2023 triple-blind randomized clinical trial enrolled 58 infertile women with diagnosed polycystic ovary syndrome and gave them either placebo or astaxanthin at 2 x 6 mg per day for 8 weeks [3]. Blood pressure was assessed at the start and end of the study, alongside fasting insulin, fasting blood glucose, oxidative stress markers and lipid panels.
After 8 weeks the trial reported significant reductions in fasting blood sugar, HOMA-IR, fasting insulin, malondialdehyde, LDL-C and the total-cholesterol-to-HDL ratio, and significant increases in total antioxidant capacity, HDL-C and QUICKI [3]. Blood pressure is not in that list, despite having been measured.
The authors also did something many supplement trials skip: they adjusted for baseline age, BMI and baseline biochemical values. After adjustment, QUICKI and fasting insulin became non-significant [3]. The other findings held. That is a well-run study reporting against its own interest, and it is more informative than a study that only tells you what worked.
Why Rat Hypertension Does Not Transfer Cleanly
The workhorse model in this literature is the spontaneously hypertensive rat, a strain bred to develop high blood pressure. It is a useful model, but it differs from human hypertension in ways that matter here. The rat model is genetically driven and uniform; human hypertension is heterogeneous, usually multifactorial, and typically arrives with decades of vascular remodeling behind it. Doses used in rodent work also frequently exceed, on a body weight basis, what an 8 or 12 mg human capsule delivers.
None of that means the rodent findings are wrong. It means they are a hypothesis about humans, and the human trials that tested that hypothesis have not confirmed it.
What This Means If You Take Astaxanthin
If you are taking astaxanthin for other reasons, nothing here is a safety concern. The trials in these analyses did not report blood pressure harm, and our side effects review covers the tolerability picture in full.
If you are taking astaxanthin specifically to lower blood pressure, the honest read is that you are acting ahead of the evidence. Two meta-analyses have looked and neither found an effect. That is not the same as proof of no effect, and a future trial designed around blood pressure as a primary endpoint in genuinely hypertensive participants could change the picture. But that trial has not been run.
If your blood pressure is high enough to need managing, it needs managing with something that has been shown to manage it. Talk to your clinician before adding a supplement, and see our drug interactions guide if you are already on antihypertensive medication.
How This Fits The Rest Of The Evidence
This is now a recognizable pattern on this site. Astaxanthin has encouraging preclinical data and a thin human record in kidney health, and in liver health the human meta-analysis actually ran against the animal data. Blood pressure belongs in the same category: a strong mechanistic story, a supportive animal literature, and human trials that have so far declined to cooperate.
Where the human evidence is genuinely better, such as eye fatigue and skin, we say so. It is not better here.
Frequently Asked Questions
Does astaxanthin lower blood pressure in humans?
Not according to the pooled human evidence. A 2020 meta-analysis of 14 randomized controlled trials found astaxanthin was not associated with either systolic or diastolic blood pressure. The belief that it lowers blood pressure comes largely from studies in spontaneously hypertensive rats, which have not been confirmed in human trials.
Why do so many sources say astaxanthin is antihypertensive?
Because the animal literature genuinely supports it. A 2017 cardiovascular review lists antihypertensive activity among astaxanthin effects, but that same review grades the underlying evidence as strong in vitro, moderate in animals and weak in humans. Many consumer pages repeat the effect and drop the grading.
Does astaxanthin improve cholesterol?
The evidence is marginal and inconsistent. A 2020 meta-analysis found a small but statistically significant HDL increase of about 1.5 mg/dL and no change in total cholesterol, LDL-C or triglycerides. An earlier meta-analysis of 7 trials found no significant effect on HDL-C at all (p = 0.199). Two reviews disagreeing on a small effect is what a marginal result looks like.
Is there any inflammation benefit at all?
Yes, but only under specific conditions. In the 2020 meta-analysis, C-reactive protein fell only when astaxanthin was taken for at least 12 weeks and only at doses above 12 mg per day. That is an inflammatory marker, not a blood pressure result, and the two should not be presented interchangeably.
Can I take astaxanthin with blood pressure medication?
Discuss it with your prescriber first. Astaxanthin has not shown a blood pressure lowering effect in pooled human trials, so it is unlikely to compound a medication effect, but interaction questions depend on your specific drugs. Our drug interactions guide covers what is known.
References
- Xia W, et al. The effects of astaxanthin supplementation on obesity, blood pressure, CRP, glycemic biomarkers, and lipid profile: A meta-analysis of randomized controlled trials. Pharmacol Res. 2020;161:105113. PMID 32755613
- Ursoniu S, et al. Lipid profile and glucose changes after supplementation with astaxanthin: a systematic review and meta-analysis of randomized controlled trials. Arch Med Sci. 2015;11(2):253-266. PMID 25995739
- Jabarpour M, et al. Astaxanthin supplementation impact on insulin resistance, lipid profile, blood pressure, and oxidative stress in polycystic ovary syndrome patients: A triple-blind randomized clinical trial. Phytother Res. 2024;38(1):321-330. PMID 37874168
- Visioli F, Artaria C. Astaxanthin in cardiovascular health and disease: mechanisms of action, therapeutic merits, and knowledge gaps. Food Funct. 2017;8(1):39-63. PMID 27924978
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.
